We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

Accelerate Immunotherapy Development

Learn how to accelerate immune therapy development from pre-clinical to clinical stages with IsoPlexis’ Single-Cell Functional Proteomics.

Your data is secure

We keep your personal information safe and do not share it with any third parties. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy. You may unsubscribe at any time.

What's Inside

In this we discuss:

Introduction to Cell Therapy: CAR-T therapies have transformed Immunotherapy
Introduction to Checkpoint Therapy: an overview and analysis
IsoPlexis' three-step single-cell proteomics workflow
Single-Cell Functional Proteomics: a power tool for immune profiling
A Deeper Look

More about this

Accelerating Novel Immunotherapies

In developing immunotherapies, processes and biomarkers are made more complex by the highly heterogenous T cells that form the basis for the therapeutic product or drive the anti-tumor response in various checkpoint and antibody-based immunotherapies.

IsoPlexis provides actionable potency, safety, and patient-difference metrics by detecting highly potent single-cell functional subsets.

Download this eBook to learn how these technological advancements are drastically accelerating the development of novel immunotherapies.

Get the